Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Literature Review Volume 3 Issue 3

Molecular-Virusological Antiproteinasno Therapy Grippa (Review of Literature and Own Research)

Valentina Divocha*

Luhansk State Medical University of Ukraine, Rubezhnoe, Ukraine

*Corresponding Author: Divocha VA, Luhansk State Medical University, Rubezhnoe, Ukraine.

Received: December 23,2019; Published: February 26, 2020



  New ways of approaching the problem of obtaining antiviral drugs based on fundamental research into the mechanisms of virus reproduction and their interaction with the host's body, using its proteolytic system, have been outlined. There are two ways to protect the virus-stricken cell in two ways: blocking the breakdown of hemagglutinin of the influenza virus by specific antibodies in the intercellular space and blocking the thripsin-like protein sprocage inhibitor hemagglutinin precursor protein in the cell itself.

Keywords: Serine Proteinase; Inhibitors; Flu



  1. Gendon YS. “Vaccines and chemotherapy drugs for the prevention of influenz”. Virology 52.1 (2007):  4-10.
  2. Slepushkin AN. “WHO World Programme for Epidemiological Surveillance and Influenza Control”. Voprosy Virusologii 1 (2003): 46-48.
  3. Kolobukhina LV. “Influenza Treatment and Prevention”. RMJ 12.17 (2004): 16-17. 
  4. Burtseva EI. “Specific prevention of influenza in the current epidemic process: autoref. dis. for the ph.d. of”. Medical Sciences (2005): 53.
  5. OI Kiselyov., et al. “Results of the clinical study of the reactogenicity, safety and immunogenicity of Grifor vaccines on the elderly contingent (60 years and older)”. Epidemiology 4.41 (2008): 36-39.
  6. EN Burtseva., et al. “Sensitivity to remantadine and arbidol influenza viruses, which caused epidemic rises in the incidence in Russia in the 2004-season”. Voprosy Virusologii 52.2 (2007):24-29.
  7. ES Shevchenko., et al. “Specific anti-influenza chemotherapy drugs, justification for their use for prevention and treatment in Russia”. Topical issues of infectious pathology and vaccine prevention in children (2007): 13-14.
  8. PG Derebin., et al. “Antiviral activity of drugs Ferrovir and Derinap in relation to infection caused by the pathogenic variant of influenza A virus (H5N1) 1 (2006): 62-65.
  9. Savinova OV., et al. “Individual and joint use of new derivatives of betuline and remantadine to inhibit reproduction of influenza virus”. Modern problems of human infectious pathology: Sat. Scientific. Works 1 (2008): 137-141.
  10. Divocha VA., et al. “Cell Proteas of the influenza virus”. Theses reports of the 2nd Congress of Infectious Diseases of the USSR K (1983): 36-38.
  11. Divocha VA. “Studying of proteolytic activity in the process of purification of influenza virus by centrifugation”. Odessa Medical Journal 1 (2003):16-19.
  12. Divocha VA. “Cell components associated with influenza virus”. Odessa Medical Journal 2.46 (1998): 8-10.
  13. Divocha VA., et al. “Proteolytic lung enzymes associated with influenza virus” Materials of the 12th Congress of microbiologists, epidemiologists and parasitologists (1996): 147-148.
  14. Divocha VA. “Cell trypsin-like proteaza is a marker of the quality of the purification of the influenza virus”. Actual Medical Biotechnology Issues (1991): 30-31.
  15. Zhirnov OP and AG Bukrinskaya. “Study of the proteins of the Sendai virus: proteolytic activity in viral particles”. Virology Issues 5 (1977): 571-577.
  16. Dool TR and Colen T. “Observations and implications of proteolysis in preparation of foot and mouth disease virus”. Developmental Biology Stand 50 (1981): 261-266.
  17. Grubman Marvin J. “Fur there characterization of a proteinkinase from foot-and-morith disease virus”. Journal of Virology 44.3 (1982): 1102-1105.
  18. Wolfram H Qerlich., еt al.  “Specificity and localization of the hepatitis B virus associated protein kinase”. Journal of Virology 42.3 (1982): 761-766.
  19. Rovnova ZI and PN Kosiakov. “The chlorina s.I. study of the properties of host antigens in the structure of microviruses”. Virology Issues 4 (1966): 413-417.
  20. Chepulis GKS and VM Yudanov. “Biological role of host antigens in mixoviruses”.  Virology Issues 2 (1968): 151-162.
  21. EA Friedman and GM Bohnevich. “Antigens host in the structure of influenza viruses”. Killed Influenza Vaccine (1976): 163-173.
  22. AL Platonova., et al. “Identification and identification of the host cell antigen as part of influenza virus B”. Virology Issues 3 (1987): 159-163.
  23. MN Matrosovich., et al. “Immunoenzyme analysis of "non-albumin" substrate impurities in inactivated influenza vaccines”. Virology Issues 4 (1989): 491-495.
  24. Divocha VA. “Cell components associated with influenza virus”. Odessa Medical Journal 2.46 (1998): 8-10.
  25. Divocha VA. “Influenza virus and enzymes cells”. Experimental and Clinical Medicine (1999): 100-105.
  26. Polyanskaya NJ and AB Jebrun. “Allantois neoalbumincomponents of whole-virion influenza vaccines”. Chromatography in Biology and Medicine: Science (1983): 249-250.
  27. Zhdanov VM., et al. “Family Orthomyxoviridae”. Private Virology 2 (1982): 139-185.
  28. Webster RQ and WQ Laver. “Antigenic variations of influenza viruses The influenza viruses and influenza (E. D. Kilbourn)”. Academia Research (1975): 209-314.
  29. AB Zhebrun., et al. “Host antigens in purified preparations of the influenza virus”. Etiology and Specific Prophylaxis of Influenza (1982): 70-81.
  30. Zorin NA. “The role of macroglobulin proteins in the mechanisms of infection”. Yu MEI 3 (2004):  105-112.
  31. Kurchenko GA. “Proteinase of chicken embryo cells and their role in the reproduction of viruses: autoref. Dis. to study. Kanda degree”. Biological Sciences (1974): 21.
  32. Bainter K and G Feher. “Fate of egg white tripsin inhibitor and start of proteolysis in developing chick embryo and nervy hatched chick”. Development Biology 36 (1973): 272-278.
  33. H Lineweaver and CW Murray. “Identification of the trypsin inhibitor of egg white ovomucoid”. Journal of Biological Chemistry 171 (1947): 565-581.
  34. Sciedl DS. et al. “Practical characterization of a subtilisin inhibitor from black bеan sceds”. International Journal of Peptide and Protein Research 19 (1982):  153-157. 
  35. T Ikenaka., еt al. “Amino acid sequence of an alkaline protease inhibitor (Streptomyces subtilisin inhibitor) from Streptomyces”. Journal of Biochemistry 76 (1974):  1191-1209.
  36. Levine A and Ginsberg. “Mechanisms by which fiber antigen inhibits multiplication of type 5 adenovirus” Journal of Virology 1 (1967): 747-757.
  37. B Baxt and R Bablanian. “Mechanisms of VSV-induced cytopathic effects”. Virology 72 (1976): 72 382-392.
  38. Hill T., et al. “Herpes simplex virus type 1 and 2 induce shutoff of host protein synthesis by different mechanisms in Friend erythroleukemie cells”. Journal of Virology 45 (1983):  241-250.
  39. Divocha VA., et al. “Change of protease activity in the lungs of mice infected with influenza virus A”. Issues of Virology 5(1999):  370-377.
  40. Divocha VA. “Changes in chicken embryo under the action of strain Virus”. Odessa Medical Journal 2 (2000):  100-105.
  41. Ewasyshyn ME and LR Sabina. “The activity of the protease of allantoic fluid in the process of infection with the influenza virus”. Асta Virology 30 (1986): 109-118.
  42. DivochaV A., et al. “Dynamics of changes of proteolytic activity of enzymes in the process of development of influenza virus B”. Bulletin of Scientific Researches 4 (2006): 51-53.
  43. Divocha VA., et al. “The separation and purification of trypsin proteases from the lungs of white mice”. Medical Chemistry 3.3 (2001): 73-77.
  44. AM Dannenberg and EL Smith. “Proteolytic enzymes of lang”. Journal of Biological Chemistry 215.1 (1955): 45-53.
  45. Divocha VA., et al. “Study of physical-chemical properties of isenzymes of Trypsin proteases”. Medical Chemistry 3.4 (2001): 31-34.
  46. GG Skehel., et al. “Changes in the conformation of influenza virus hemagglutinin at the ph optimum of virus-mediated membrane fusion”. Proceedings of the National Academy of Sciences79.4 (1982): 968-972.
  47. R Rott., et al.  “Influenza viruses, cell enzymes and pathogenicity” American Journal of Respiratory and Critical Care Medicine 152 (1995): 516-519.
  48. Divocha VA., et al. “Defensive role of anti-proteous immune serums in experimental influenza”. Mechnikov and development of modern natural science”. Conf (1995): 102-103.
  49. Divocha VA. “Protective action of antiproteic whey”. Odessa Medical Journal 371 (2002): 14-17.
  50. VP Lozitsky., et al. “The participation of the proteolysis system in the implementation of the virulence of the influenza virus and the development of the infectious process: the antiviral effect of protease inhibitors”. Questions of Virology 4 (1987): 413-419.
  51. W Weis., еt al.  “Structure of the influenza virus hemagglutinin complexed with its receptor, silica acid”. Nature 333.6172 (1988): 426-431.
  52. Scholtissek C. “Influenza A viruses with noucleaved hemagglutinin are not internalised after adsorbtion”. Archives of Virology 90.12 (1986): 159-163.
  53. Maleev Yu Z. “The role of neuraminidase inhibitors in the prevention and treatment of influenza”. Kidney Pharmacology and Therapeutics (2007): 1-6.
  54. LV Kolobukhina., et al.  “The effectiveness of oseltamivir (Tamiflu)in influenza in adults during the epidemic rise of morbidity in Russia in the season 2006 -2007 г.g”. Invo virology 4 (2008):  23-27.
  55. Veremeenko KN., et al. “Proteolysis in normal and in pathology”. Health (1988): 200.
  56. Divocha VA. “NBP Method of receiving a tripsinoid protease inhibitor”. Applicant and Patentoholder Divocha (2019).
  57. Nagai Y., et al. “An endoprotease homologous to the blood clotting factor X as a determinant of viral tropism in chick embryo”. The EMBO Journal 9.12 (1990): 4189-4195. 
  58. Bin Goton., еt al.  “An endoprotease homologons to the blood clotting factor X as a determinant of viral tropism in chick embryo”. JORNAL EMBO 9.12 (1990): 4189-4195.
  59. SM Podyarene., et al. “Immunoafin cleaning a1 - protease inhibitor from human blood plasma”. Virology Issues 5 (1989): 96-99.
  60. Markov OA. et al.  “Immunoenzyme method of antithrombin detection 3”. Medical Chemistry 5 (1989): 127-130.


Citation: Valentina Divocha. “Molecular-Virusological Antiproteinasno Therapy Grippa (Review of Literature and Own Research)". Acta Scientific Microbiology 3.3 (2020): 01-08.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US